Open Source Imaging Consortium
OSIC is a global 501(c)(3) nonprofit cooperative operating the world's largest interstitial lung disease data repository (20,789+ anonymized HRCT scans), serving academic, pharmaceutical, medical imaging AI, and patient advocacy members through collaborative research and open-source AI tooling.
- Company typePrivate
- Founded2019
- HeadquartersSaugatuck, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Open Source Imaging Consortium does
Open Source Imaging Consortium (OSIC) is a global, 501(c)(3) nonprofit cooperative founded in May 2019 and headquartered in Holland, Michigan. The organization was created to advance research in interstitial lung diseases (ILDs) and rare fibrosing lung conditions by uniting academic institutions, pharmaceutical and biotechnology companies, medical imaging/AI vendors, and patient advocacy groups in pre-competitive collaboration. Its central asset is the OSIC Cloud Data Repository, the world's largest and most diverse ILD database, containing more than 20,789 anonymized HRCT scans with accompanying clinical data sourced from institutions across the US, EU, Asia, and Latin America — surpassing the consortium's original 15,000-scan goal.
The technology backbone is the OSIC Cloud, powered by VIDA Diagnostics, providing a secure, AI-ready, GDPR/HIPAA-compliant environment with automated pseudonymization, role-based access controls, multi-omic capability, and 13+ language support, governed under a U.S. Central IRB (Advarra) and multiple institutional IRBs. OSIC has developed and released open-source AI assets, notably CenTime (an event-conditional survival analysis model built with University College London), and runs scientific challenges (two Kaggle competitions engaging 2,500+ competitors) and working groups across data architecture, biomarkers, governance, and challenges. The platform's outputs underpin externally validated, FDA-cleared products such as 4DMedical's IQ-UIP and Coreline Soft's eFVC.
OSIC's business model is a membership consortium: 50+ institutional partners (including founding members Boehringer Ingelheim, Siemens Healthineers, CSL Behring, and FLUIDDA) commit multi-year funding and/or imaging and clinical data contributions in exchange for repository access, working-group participation, and collaborative research rights. Revenue is not publicly disclosed and the entity has no venture capital, private equity, or parent company ownership; governance sits with a Board of Directors, Core Science Leadership Team, and working-group structure. Go-to-market is community-led and event-driven, anchored by an annual member meeting (Amsterdam 2025, Barcelona 2026), peer-reviewed publication output (100+ publications), and thought-leadership content such as The Lung Lab podcast.
Open Source Imaging Consortium firmographics
Firmographics- Name
- Open Source Imaging Consortium
- Legal name
- Open Source Imaging Consortium, Inc.
- Website
- https://osicild.org
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OSIC is a global 501(c)(3) nonprofit cooperative operating the world's largest interstitial lung disease data repository (20,789+ anonymized HRCT scans), serving academic, pharmaceutical, medical imaging AI, and patient advocacy members through collaborative research and open-source AI tooling.
- Ownership category
- akta.pro rank
Open Source Imaging Consortium industry classification
Industry- Product category
- Medical Imaging Research Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
Keywords
Where Open Source Imaging Consortium is headquartered
LocationHeadquarters
- HQ city
- Saugatuck
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Open Source Imaging Consortium business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Institutional Membership Fees: OSIC is a 501(c)(3) nonprofit that generates revenue through multi-year institutional membership commitments from academic, industry, and patient advocacy partners. Members receive access to the OSIC Cloud Data Repository, platform usage, and collaborative research resources.
- Collaborative Research Contributions: Partners contribute funding and/or pledge to contribute with imaging and clinical data to support OSIC operations. These multi-year commitments of funding support the consortium's mission to advance ILD research.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels8 records
Open Source Imaging Consortium product offering
Product offeringCore offering
OSIC operates the OSIC Cloud Data Repository, the world's largest and most diverse anonymized HRCT imaging and clinical dataset for interstitial lung disease (ILD) research, comprising more than 20,789 committed scans from global academic and industry sources. Member institutions access this AI-ready, GDPR/HIPAA-compliant platform to train and validate imaging algorithms, develop digital biomarkers, and conduct collaborative research. Complementary offerings include the open-source CenTime survival-analysis model built with UCL, the longitudinal Project OPUS study, scientific working groups, and structured challenges (Kaggle and Imaging Consensus) that enable pre-competitive collaboration among academia, pharma, medical-imaging AI companies, and patient advocacy groups.
Product overview
Open Source Imaging Consortium (OSIC) is a global, 501(c)(3) nonprofit cooperative that operates a suite of interconnected products and initiatives focused on revolutionizing research in interstitial lung diseases (ILDs) and rare fibrosing lung conditions through digital imaging and machine learning. The core product is the OSIC Cloud Data Repository—the world's largest and most diverse ILD database with over 20,789 anonymized HRCT scans and accompanying clinical data. Supporting the repository is CenTime, an open-source survival analysis tool developed with UCL that demonstrates state-of-the-art performance in event-conditional modeling. Project OPUS provides a longitudinal study framework for consented ILD patients. Additional offerings include The Lung Lab podcast, Kaggle challenges for algorithm development, and upcoming initiatives including the Imaging Consensus Initiative and PCCT Readiness Initiative (both launching in 2026). The organization also facilitates peer-to-peer collaboration through five Working Groups focused on data architecture, curation, challenges, governance, and biomarkers. All digital biomarkers and algorithms developed are released open source for the benefit of patients worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- OSIC Cloud: The OSIC Cloud Data Repository - a secure platform for managing de-identified, curated real-world and clinical trial data designed to fuel collaborative lung disease research.
- CenTime
- Project OPUS
- Imaging Consensus Initiative
- PCCT Readiness Initiative
- The Lung Lab
Products and services
- OSIC Cloud Data Repository Secure, AI-ready platform housing the world's largest and most diverse global database of anonymized HRCT scans with accompanying clinical data for interstitial lung disease research, accessible to OSIC member institutions for algorithm training, biomarker discovery, and trial endpoint refinement.
- CenTime Open-source survival analysis model that directly estimates time-to-event occurrence for disease progression prediction in respiratory health, using an event-conditional censoring mechanism and performing robustly even with limited uncensored data.
- Project OPUS (OSIC Pulmonary Understanding Study) Longitudinal study framework capturing prospective, multi-omic clinical and imaging data from consented ILD patients worldwide, aligned to modern research needs and feeding the OSIC Cloud Data Repository.
- Imaging Consensus Initiative Scientific challenge launching in 2026 designed to characterize agreement and divergence among imaging AI algorithms across fibrotic lung disease, enabling the field to map consensus and uncertainty.
- PCCT Readiness Initiative
Quantifiable outcome
- 100+ peer-reviewed publications leveraging OSIC data
- +2 more outcomes
Companies that use Open Source Imaging Consortium
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Open Source Imaging Consortium technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Open Source Imaging Consortium partnerships and signals
Strategic signalPartnerships
30 partnerships are on record, tiered core, key, founding and general.
- Baillie Gifford Pandemic Science Hub at University of EdinburghcoreProject Cairn collaboration to create a Rare Lung Disease Intelligence Engine by integrating global imaging data, clinical information, and phenotype within a secure compute environment. Combines OSIC's globally harmonized dataset with infrastructure from the Baillie Gifford Pandemic Science Hub, enabling large-scale integrated analysis across imaging, clinical, and biological data.
- Medicom TechnologieskeyPartnership to help continue adding anonymized, comprehensive data sets to the OSIC Data Repository, expanding the diversity and scale of available clinical data.
- Boehringer IngelheimfoundingFounding pharmaceutical partner of OSIC. One of the world's leading research-driven pharmaceutical companies contributing to the consortium's mission to advance ILD research.
- Siemens HealthineersfoundingFounding industry partner, one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, and health IT.
- CSL BehringfoundingFounding biotechnology partner, one of the world's largest driven by its promise to help patients lead full lives with therapies for coagulation disorders, primary immune deficiencies, and respiratory diseases.
- FLUIDDAfoundingFounding partner and world leader in Functional Respiratory Imaging (FRI) research and development, providing respiratory solutions for better patient care.
- VIDA DiagnosticscorePlatform partner powering the OSIC Cloud, a secure platform for managing de-identified, curated real-world and clinical trial data designed to fuel collaborative lung disease research.
- University College London (UCL)coreKey academic partner providing computational science leadership (Prof. David Barber) and radiology leadership (Prof. Joseph Jacob). Collaborator on CenTime development.
- National Jewish HealthcoreKey academic partner providing pulmonology leadership (Dr. Kevin Brown). Major contributor of patient data and research expertise.
- University of California, San DiegocoreAcademic partner providing US radiology leadership (Dr. Jonathan Chung). Collaborates on ILD research and imaging biomarker development.
- ThironakeyMedical imaging technology partner specializing in quantitative analysis for ILD research and lung disease imaging.
- Coreline SoftkeyMedical AI imaging partner that developed estimated FVC (eFVC) using OSIC data. First Korean medical AI company with ISO/IEC AI 24001 certification and FDA 510(k) clearance.
- 4DMedicalkeyMedical technology partner with FDA-cleared IQ-UIP software developed using OSIC data. Contributed to regulatory activities and development of AI imaging solutions.
- BrainomixkeyAI-powered imaging biomarkers partner developing e-ILD software for ILD assessment, using OSIC Data Repository for refinement and validation.
- American Lung AssociationkeyPatient advocacy partner helping ensure patient perspectives are central to research priorities and that advances benefit patients directly.
- European Pulmonary Fibrosis Federation (EU-PFF)keyEuropean patient advocacy organization working to improve outcomes for people with pulmonary fibrosis.
- PF WarriorskeyPatient advocacy organization providing patient and caregiver perspectives to guide research direction.
- Action for Pulmonary FibrosiskeyUK-based patient advocacy organization dedicated to finding answers and providing support for those affected by pulmonary fibrosis.
- Foundation for Sarcoidosis Research (FSR)keyLeading international nonprofit dedicated to finding a cure for sarcoidosis and improving care through research, education, and support.
- Critical Path Institute (C-Path)keyCollaborative partner in the CPA-1 program bringing gene editing innovation and global lung imaging data resources to advance therapies for alpha-1 antitrypsin deficiency.
- contextflowgeneralAI imaging partner that analyzed data from OSIC Cloud lung cancer screening/ILA cohort to identify proof of concept for AI risk scoring.
- Medical University of ViennakeyKey academic partner providing radiology expertise and research contributions to ILD imaging biomarker development.
- University of FloridakeyMajor academic contributor that has contributed more than 1,000 anonymized patient cases to the OSIC Cloud Data Repository.
- GenentechkeyBiotechnology partner contributing to the consortium's pharmaceutical and research collaborations in respiratory disease.
- GalapagoskeyBiopharmaceutical partner contributing to collaborative research efforts in fibrotic lung diseases.
- GMVgeneralTechnology partner using OSIC data repository in its SEPI-IA research initiative developing AI tools for medical imaging of rare respiratory diseases.
- Stanford MedicinekeyMajor academic medical center contributing to the consortium's research network and data sharing efforts.
- Imperial College London (National Heart and Lung Institute)coreKey academic partner providing radiology leadership expertise for ILD research and AI biomarker development.
- Carestream HealthkeyMedical imaging partner funding Project OPUS to explore potential of X-ray imaging for earlier diagnosis and disease management of IPF.
- KagglekeyGlobal online competition platform hosting OSIC's Pulmonary Fibrosis Progression Challenges with over 5 million registered users from 250 countries.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Open Source Imaging Consortium competitors and assessment
Company assessmentDirect peers
- VIDA Diagnostics: Iowa-based lung imaging AI company that powers the OSIC Cloud platform. Provides the underlying infrastructure for OSIC's data repository and develops its own quantitative lung imaging products.
- contextflow: Vienna-based AI radiology company that used OSIC Cloud data to develop its ILA/ILD risk scoring proof of concept. Operates in the same imaging AI category serving similar pharma and clinical customers.
- Brainomix: UK-based AI imaging company developing e-ILD for ILD assessment using OSIC's anonymized HRCT repository. Brainomix's CMIO also chairs the OSIC Board, evidencing deep two-way collaboration.
- Coreline Soft: Korean medical AI company that developed the eFVC quantitative imaging metric using OSIC data as its primary training set. First Korean firm with ISO/IEC AI 24001 certification and FDA 510(k) clearance for chest CT AI.
- FLUIDDA: Belgian functional respiratory imaging company and OSIC founding partner. Develops FRI-based biomarkers for respiratory drug development, serving the same pharma customer base for ILD trial endpoints.
- 4DMedical: Australia-listed lung imaging AI company whose FDA-cleared IQ-UIP software for UIP detection was developed using the OSIC data repository. Directly consumes OSIC data and develops competing/complementary ILD AI products.
- Thirona: Dutch quantitative lung imaging company specializing in CT-based analysis for ILD and other lung diseases. Listed OSIC technology partner with overlapping product/customer base.
Emerging players
- Quibim: Spain-based AI radiology platform company with whole-body imaging AI capabilities that overlap with OSIC's pulmonary focus. Builds regulatory-grade imaging biomarkers for pharma sponsors.
Broad incumbents
- Siemens Healthineers: Global medical imaging incumbent and OSIC founding industry partner. Offers competing AI-Rad Companion chest CT capabilities at scale but as part of a broader imaging portfolio rather than an ILD-specialized focus.
Others
- Critical Path Institute: Public-private partnership that operates the CPA-1 program with OSIC for alpha-1 antitrypsin deficiency. Functions as an adjacent consortium/regulatory-science enabler rather than a direct AI imaging competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Open Source Imaging Consortium social profiles
Digital presenceOpen Source Imaging Consortium compliance and trust
Trust signalCompliance3 records
Open Source Imaging Consortium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Open Source Imaging Consortium leadership team
Management profileNumber of profiles
Profiles18 records
Open Source Imaging Consortium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Open Source Imaging Consortium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Open Source Imaging Consortium
What does Open Source Imaging Consortium do?
OSIC operates the OSIC Cloud Data Repository, the world's largest and most diverse anonymized HRCT imaging and clinical dataset for interstitial lung disease (ILD) research, comprising more than 20,789 committed scans from global academic and industry sources. Member institutions access this AI-ready, GDPR/HIPAA-compliant platform to train and validate imaging algorithms, develop digital biomarkers, and conduct collaborative research. Complementary offerings include the open-source CenTime survival-analysis model built with UCL, the longitudinal Project OPUS study, scientific working groups, and structured challenges (Kaggle and Imaging Consensus) that enable pre-competitive collaboration among academia, pharma, medical-imaging AI companies, and patient advocacy groups.
Is Open Source Imaging Consortium a public or private company?
Open Source Imaging Consortium is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Open Source Imaging Consortium founded?
Open Source Imaging Consortium was founded in 2019. It employs 1 to 10 people.
Where is Open Source Imaging Consortium based?
Open Source Imaging Consortium is headquartered in Saugatuck, United States, in the North America region.
How does Open Source Imaging Consortium make money?
Two revenue lines are on record. Institutional Membership Fees are the primary driver. The others are collaborative Research Contributions.
Who are Open Source Imaging Consortium's main competitors?
Direct peers on record are VIDA Diagnostics, contextflow, Brainomix, Coreline Soft, FLUIDDA, 4DMedical and Thirona. Quibim is listed as an emerging player. Siemens Healthineers is listed as a broad incumbent. Critical Path Institute is listed as an others.
Does Open Source Imaging Consortium have an API?
No public API is recorded for Open Source Imaging Consortium.
What industry is Open Source Imaging Consortium in?
Open Source Imaging Consortium's product category is Medical Imaging Research Platform. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 541714 and its SIC code is 8731.